Onderzoeksoutput per jaar
Onderzoeksoutput per jaar
- 6 resultaten
Zoekresultaten
-
2023
Targeting DNMT3B impairs multiple myeloma cell proliferation and clonogenic capacity and enhances sensitivity to standard of care agents.
Muylaert, C., Van Hemelrijck, L. A., Alaterre, E., Robert, N., Requirand, G., De Veirman, K., Menu, E., Vanderkerken, K., Moreaux, J. & De Bruyne, E., sep 2023.Onderzoeksoutput: Poster
-
2022
Targeting of DNMT3B in the plasma cell cancer multiple myeloma disturbs cancer cell growth and clonogenicity and boosts the anti-tumor activity of the proteasome inhibitor bortezomib
Muylaert, C., Van Hemelrijck, L. A., Vlummens, P., Maes, A., De Veirman, K., Menu, E., De Bruyne, E. & Vanderkerken, K., jun 2022.Onderzoeksoutput: Poster
-
Targeting of DNMT3B in the plasma cell cancer multiple myeloma disturbs cancer cell growth and clonogenicity and boosts the anti-tumor activity of the proteasome inhibitor bortezomib.
Muylaert, C., Van Hemelrijck, L. A., Vlummens, P., Maes, A., De Veirman, K., Menu, E., Vanderkerken, K. & De Bruyne, E., 30 sep 2022.Onderzoeksoutput: Poster
-
The de novo DNA methyltransferase DNMT3B: A new promising target in multiple myeloma
Muylaert, C., Van Hemelrijck, L. A., Maes, A., De Veirman, K., Menu, E., Vanderkerken, K. & De Bruyne, E., 2022.Onderzoeksoutput: Poster
-
The De Novo DNA Methyltransferase DNMT3B Plays an Important Role in MM Cell Growth, Clonogenicity and Drug Response
Muylaert, C., Van Hemelrijck, L. A., Maes, A., De Veirman, K., Menu, E., Vanderkerken, K. & De Bruyne, E., 9 jun 2022.Onderzoeksoutput: Poster
-
The de novo DNA methyltransferase DNMT3B plays an important role in multiple myeloma cell growth, clonogenicity and drug response
Muylaert, C., Van Hemelrijck, L. A., Vlummens, P., De Veirman, K., Menu, E., Vanderkerken, K. & De Bruyne, E., 2022.Onderzoeksoutput: Poster